127 related articles for article (PubMed ID: 9858317)
1. Impact of RNase L overexpression on viral and cellular growth and death.
Zhou A; Paranjape JM; Hassel BA; Nie H; Shah S; Galinski B; Silverman RH
J Interferon Cytokine Res; 1998 Nov; 18(11):953-61. PubMed ID: 9858317
[TBL] [Abstract][Full Text] [Related]
2. Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta.
Rusch L; Zhou A; Silverman RH
J Interferon Cytokine Res; 2000 Dec; 20(12):1091-100. PubMed ID: 11152576
[TBL] [Abstract][Full Text] [Related]
3. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L.
Zhou A; Paranjape J; Brown TL; Nie H; Naik S; Dong B; Chang A; Trapp B; Fairchild R; Colmenares C; Silverman RH
EMBO J; 1997 Nov; 16(21):6355-63. PubMed ID: 9351818
[TBL] [Abstract][Full Text] [Related]
4. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L.
Malathi K; Paranjape JM; Bulanova E; Shim M; Guenther-Johnson JM; Faber PW; Eling TE; Williams BR; Silverman RH
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14533-8. PubMed ID: 16203993
[TBL] [Abstract][Full Text] [Related]
5. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection.
Li XL; Blackford JA; Hassel BA
J Virol; 1998 Apr; 72(4):2752-9. PubMed ID: 9525594
[TBL] [Abstract][Full Text] [Related]
6. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system.
Castelli JC; Hassel BA; Wood KA; Li XL; Amemiya K; Dalakas MC; Torrence PF; Youle RJ
J Exp Med; 1997 Sep; 186(6):967-72. PubMed ID: 9294150
[TBL] [Abstract][Full Text] [Related]
7. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.
Xiang Y; Wang Z; Murakami J; Plummer S; Klein EA; Carpten JD; Trent JM; Isaacs WB; Casey G; Silverman RH
Cancer Res; 2003 Oct; 63(20):6795-801. PubMed ID: 14583476
[TBL] [Abstract][Full Text] [Related]
8. The association of elevated 2',5'-oligoadenylate-dependent RNase L with lung cancer correlated with deficient enzymatic activity and decreased capacity of RNase L dimerization.
Yin H; Zhou A; Dai Y
Lung Cancer; 2012 Oct; 78(1):30-8. PubMed ID: 22925698
[TBL] [Abstract][Full Text] [Related]
9. The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis.
Castelli JC; Hassel BA; Maran A; Paranjape J; Hewitt JA; Li XL; Hsu YT; Silverman RH; Youle RJ
Cell Death Differ; 1998 Apr; 5(4):313-20. PubMed ID: 10200477
[TBL] [Abstract][Full Text] [Related]
10. Localization of a molecular form of interferon-regulated RNase L in the cytoskeleton.
Tnani M; Aliau S; Bayard B
J Interferon Cytokine Res; 1998 Jun; 18(6):361-8. PubMed ID: 9660242
[TBL] [Abstract][Full Text] [Related]
11. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.
Player MR; Torrence PF
Pharmacol Ther; 1998 May; 78(2):55-113. PubMed ID: 9623881
[TBL] [Abstract][Full Text] [Related]
12. The 2-5A system in viral infection and apoptosis.
Castelli J; Wood KA; Youle RJ
Biomed Pharmacother; 1998; 52(9):386-90. PubMed ID: 9856285
[TBL] [Abstract][Full Text] [Related]
13. Characterization of RNABP, an RNA binding protein that associates with RNase L.
Le Roy F; Laskowska A; Silhol M; Salehzada T; Bisbal C
J Interferon Cytokine Res; 2000 Jul; 20(7):635-44. PubMed ID: 10926206
[TBL] [Abstract][Full Text] [Related]
14. Solid-phase synthesis of 5'-triphosphate 2'-5'-oligoadenylates analogs with 3'-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.
Thillier Y; Stevens SK; Moy C; Taylor J; Vasseur JJ; Beigelman L; Debart F
Bioorg Med Chem; 2013 Sep; 21(17):5461-9. PubMed ID: 23810677
[TBL] [Abstract][Full Text] [Related]
15. Independent regulation of ppp(A2'p)nA-dependent RNase in NIH 3T3, clone 1 cells by growth arrest and interferon treatment.
Krause D; Panet A; Arad G; Dieffenbach CW; Silverman RH
J Biol Chem; 1985 Aug; 260(16):9501-7. PubMed ID: 4019482
[TBL] [Abstract][Full Text] [Related]
16. A 2',5'-oligoadenylate analogue inhibits murine hepatitis virus strain 3 (MHV-3) replication in vitro but does not reduce MHV-3-related mortality or induction of procoagulant activity in susceptible mice.
Fingerote RJ; Cruz BM; Gorczynski RM; Fung LS; Hubbell HR; Suhadolnik RJ; Levy GA
J Gen Virol; 1995 Feb; 76 ( Pt 2)():373-80. PubMed ID: 7844557
[TBL] [Abstract][Full Text] [Related]
17. Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells.
Cirino NM; Li G; Xiao W; Torrence PF; Silverman RH
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1937-42. PubMed ID: 9050883
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule activators of RNase L with broad-spectrum antiviral activity.
Thakur CS; Jha BK; Dong B; Das Gupta J; Silverman KM; Mao H; Sawai H; Nakamura AO; Banerjee AK; Gudkov A; Silverman RH
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9585-90. PubMed ID: 17535916
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L.
Park IH; Kwon YC; Ryu WS; Ahn BY
Antiviral Res; 2014 Apr; 104():118-27. PubMed ID: 24509240
[TBL] [Abstract][Full Text] [Related]
20. Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway.
Bisbal C; Martinand C; Silhol M; Lebleu B; Salehzada T
J Biol Chem; 1995 Jun; 270(22):13308-17. PubMed ID: 7539425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
